Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Clinical trial NCT00622388 · COMPLETED

Trial details

NCT number: NCT00622388
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoma, Large-Cell, Diffuse

Start date: 2007-12-01
Primary completion: 2010-05-01
Enrollment: 81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.